Cost-Effectiveness of Ibrutinib in Patients with Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.246
https://www.valueinhealthjournal.com/article/S1098-3015(17)30580-6/fulltext
Title :
Cost-Effectiveness of Ibrutinib in Patients with Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30580-6&doi=10.1016/j.jval.2017.08.246
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
227